Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NXJ5
UPID:
PGPI_HUMAN
Alternative names:
5-oxoprolyl-peptidase; Pyroglutamyl aminopeptidase I; Pyroglutamyl-peptidase I; Pyrrolidone-carboxylate peptidase
Alternative UPACC:
Q9NXJ5; A8K1Q3; Q8IVT1
Background:
Pyroglutamyl-peptidase 1, known by alternative names such as 5-oxoprolyl-peptidase, Pyroglutamyl aminopeptidase I, and Pyrrolidone-carboxylate peptidase, plays a crucial role in protein metabolism. It specifically removes 5-oxoproline from various penultimate amino acid residues, showcasing its unique enzymatic activity.
Therapeutic significance:
Understanding the role of Pyroglutamyl-peptidase 1 could open doors to potential therapeutic strategies. Its unique enzymatic function in protein metabolism positions it as a key target for drug discovery, aiming to harness its biological activity for therapeutic benefits.